Tao Peng

List of Publications by Year in Descending Order

69 papers	3,394 citations	35 h-index	57 g-index
73 ext. papers	3,785 ext. citations	5.9 avg, IF	5.32 L-index

#	Paper	IF	Citations
69	Targeting Ubiquitin-Proteasome System With Copper Complexes for Cancer Therapy. *Frontiers in Molecular Biosciences*, **2021**, 8, 649151	5.6	5
68	Everolimus regulates the activity of gemcitabine-resistant pancreatic cancer cells by targeting the Warburg effect via PI3K/AKT/mTOR signaling. *Molecular Medicine*, **2021**, 27, 38	6.2	9
67	Repurposing old drugs as new inhibitors of the ubiquitin-proteasome pathway for cancer treatment. *Seminars in Cancer Biology*, **2021**, 68, 105-122	12.7	11
66	Updated review on green tea polyphenol epigallocatechin-3-gallate as a cancer epigenetic regulator. *Seminars in Cancer Biology*, **2021**,	12.7	3
65	Proteasome-associated cysteine deubiquitinases are molecular targets of environmental optical brightener compounds. *Journal of Cellular Biochemistry*, **2019**, 120, 14065-14075	4.7	2
64	Growth arrest and apoptosis induction in androgen receptor-positive human breast cancer cells by inhibition of USP14-mediated androgen receptor deubiquitination. *Oncogene*, **2018**, 37, 1896-1910	9.2	61
63	Computational and biochemical studies of isothiocyanates as inhibitors of proteasomal cysteine deubiquitinases in human cancer cells. *Journal of Cellular Biochemistry*, **2018**, 119, 9006-9016	4.7	7
62	Perspectives on the recent developments with green tea polyphenols in drug discovery. *Expert Opinion on Drug Discovery*, **2018**, 13, 643-660	6.2	15
61	Targeting the DNA Repair Endonuclease ERCC1-XPF with Green Tea Polyphenol Epigallocatechin-3-Gallate (EGCG) and Its Prodrug to Enhance Cisplatin Efficacy in Human Cancer Cells. *Nutrients*, **2018**, 10,	6.7	16
60	A patent review of the ubiquitin ligase system: 2015-2018. *Expert Opinion on Therapeutic Patents*, **2018**, 28, 919-937	6.8	31
59	Everolimus Inhibits Growth of Gemcitabine-Resistant Pancreatic Cancer Cells via Induction of Caspase-Dependent Apoptosis and G /M Arrest. *Journal of Cellular Biochemistry*, **2017**, 118, 2722-2730	4.7	13
58	The preclinical discovery and development of bortezomib for the treatment of mantle cell lymphoma. *Expert Opinion on Drug Discovery*, **2017**, 12, 225-235	6.2	16
57	Metal-based proteasomal deubiquitinase inhibitors as potential anticancer agents. *Cancer and Metastasis Reviews*, **2017**, 36, 655-668	9.6	28
56	Targeting the ubiquitin-proteasome system for cancer treatment: discovering novel inhibitors from nature and drug repurposing. *Cancer and Metastasis Reviews*, **2017**, 36, 717-736	9.6	59
55	l-Tryptophan Schiff base cadmium(II) complexes as a new class of proteasome inhibitors and apoptosis inducers in human breast cancer cells. *Inorganica Chimica Acta*, **2017**, 466, 478-485	2.7	13
54	P-Glycoprotein Inhibition Sensitizes Human Breast Cancer Cells to Proteasome Inhibitors. *Journal of Cellular Biochemistry*, **2017**, 118, 1239-1248	4.7	12
53	Involvement of ALAD-20S Proteasome Complexes in Ubiquitination and Acetylation of Proteasomal □ Subunits. *Journal of Cellular Biochemistry*, **2016**, 117, 144-51	4.7	7

52	Deubiquitinases (DUBs) and DUB inhibitors: a patent review. *Expert Opinion on Therapeutic Patents*, **2015**, 25, 1191-1208	6.8	72
51	Proteasome inhibitors induce AMPK activation via CaMKK□n human breast cancer cells. *Breast Cancer Research and Treatment*, **2015**, 153, 79-88	4.4	15
50	L-Ornithine Schiff base-copper and -cadmium complexes as new proteasome inhibitors and apoptosis inducers in human cancer cells. *Journal of Biological Inorganic Chemistry*, **2015**, 20, 109-21	3.7	12
49	Inhibition of 19S proteasome-associated deubiquitinases by metal-containing compounds. *Oncoscience*, **2015**, 2, 457-66	0.8	25
48	Lessons from Nature: Sources and Strategies for Developing AMPK Activators for Cancer Chemotherapeutics. *Anti-Cancer Agents in Medicinal Chemistry*, **2015**, 15, 657-71	2.2	8
47	Inhibition of the 26S proteasome as a possible mechanism for toxicity of heavy metal species. *Journal of Inorganic Biochemistry*, **2014**, 132, 96-103	4.2	3
46	Proteasome inhibitor patents (2010 - present). *Expert Opinion on Therapeutic Patents*, **2014**, 24, 369-82	6.8	2
45	Gold(III)-dithiocarbamato peptidomimetics in the forefront of the targeted anticancer therapy: preclinical studies against human breast neoplasia. *PLoS ONE*, **2014**, 9, e84248	3.7	39
44	The interplay of AMP-activated protein kinase and androgen receptor in prostate cancer cells. *Journal of Cellular Physiology*, **2014**, 229, 688-95	7	22
43	Tumor necrosis factor-□ensitizes breast cancer cells to natural products with proteasome-inhibitory activity leading to apoptosis. *PLoS ONE*, **2014**, 9, e113783	3.7	22
42	Overview of proteasome inhibitor-based anti-cancer therapies: perspective on bortezomib and second generation proteasome inhibitors versus future generation inhibitors of ubiquitin-proteasome system. *Current Cancer Drug Targets*, **2014**, 14, 517-36	2.8	173
41	Targeting the ubiquitin-proteasome system for cancer therapy. *Expert Opinion on Therapeutic Targets*, **2013**, 17, 1091-108	6.4	130
40	Regulation of metformin response by breast cancer associated gene 2. *Neoplasia*, **2013**, 15, 1379-90	6.4	15
39	Cellular and computational studies of proteasome inhibition and apoptosis induction in human cancer cells by amino acid Schiff base-copper complexes. *Journal of Inorganic Biochemistry*, **2013**, 118, 83-93	4.2	78
38	From bortezomib to other inhibitors of the proteasome and beyond. *Current Pharmaceutical Design* , **2013**, 19, 4025-38	3.3	99
37	Novel epigallocatechin gallate (EGCG) analogs activate AMP-activated protein kinase pathway and target cancer stem cells. *Bioorganic and Medicinal Chemistry*, **2012**, 20, 3031-7	3.4	86
36	Transcriptional activation of breast cancer-associated gene 2 by estrogen receptor. *Breast Cancer Research and Treatment*, **2012**, 135, 495-503	4.4	9
35	1,10-Phenanthroline promotes copper complexes into tumor cells and induces apoptosis by inhibiting the proteasome activity. *Journal of Biological Inorganic Chemistry*, **2012**, 17, 1257-67	3.7	42

34	L-carnitine is an endogenous HDAC inhibitor selectively inhibiting cancer cell growth in vivo and in vitro. *PLoS ONE*, **2012**, 7, e49062	3.7	63
33	HDAC inhibitor L-carnitine and proteasome inhibitor bortezomib synergistically exert anti-tumor activity in vitro and in vivo. *PLoS ONE*, **2012**, 7, e52576	3.7	21
32	Novel Polypyridyl chelators deplete cellular zinc and destabilize the X-linked inhibitor of apoptosis protein (XIAP) prior to induction of apoptosis in human prostate and breast cancer cells. *Journal of Cellular Biochemistry*, **2012**, 113, 2567-75	4.7	19
31	Gambogic acid enhances proteasome inhibitor-induced anticancer activity. *Cancer Letters*, **2011**, 301, 221-8	9.9	56
30	Shikonin extracted from medicinal Chinese herbs exerts anti-inflammatory effect via proteasome inhibition. *European Journal of Pharmacology*, **2011**, 658, 242-7	5.3	108
29	Modulation of the tumor cell death pathway by androgen receptor in response to cytotoxic stimuli. *Journal of Cellular Physiology*, **2011**, 226, 2731-9	7	12
28	EGCG, green tea polyphenols and their synthetic analogs and prodrugs for human cancer prevention and treatment. *Advances in Clinical Chemistry*, **2011**, 53, 155-77	5.8	137
27	Antitumor activity of novel fluoro-substituted (-)-epigallocatechin-3-gallate analogs. *Cancer Letters*, **2010**, 292, 48-53	9.9	34
26	Tumor cellular proteasome inhibition and growth suppression by 8-hydroxyquinoline and clioquinol requires their capabilities to bind copper and transport copper into cells. *Journal of Biological Inorganic Chemistry*, **2010**, 15, 259-69	3.7	104
25	Inhibition of tumor proteasome activity by gold-dithiocarbamato complexes via both redox-dependent and -independent processes. *Journal of Cellular Biochemistry*, **2010**, 109, 162-172	4.7	94
24	Proteasome inhibition in human breast cancer cells with high catechol-O-methyltransferase activity by green tea polyphenol EGCG analogs. *Bioorganic and Medicinal Chemistry*, **2010**, 18, 1252-8	3.4	41
23	Molecular mechanisms of green tea polyphenols. *Nutrition and Cancer*, **2009**, 61, 827-35	2.8	54
22	Shikonin exerts antitumor activity via proteasome inhibition and cell death induction in vitro and in vivo. *International Journal of Cancer*, **2009**, 124, 2450-9	7.5	141
21	The tumor proteasome as a novel target for gold(III) complexes: implications for breast cancer therapy. *Coordination Chemistry Reviews*, **2009**, 253, 1649-1660	23.2	123
20	Metals in anticancer therapy: copper(II) complexes as inhibitors of the 20S proteasome. *European Journal of Medicinal Chemistry*, **2009**, 44, 4353-61	6.8	85
19	Clinical development of novel proteasome inhibitors for cancer treatment. *Expert Opinion on Investigational Drugs*, **2009**, 18, 957-71	5.9	75
18	The proteasome is a molecular target of environmental toxic organotins. *Environmental Health Perspectives*, **2009**, 117, 379-86	8.4	32
17	Disulfiram promotes the conversion of carcinogenic cadmium to a proteasome inhibitor with pro-apoptotic activity in human cancer cells. *Toxicology and Applied Pharmacology*, **2008**, 229, 206-14	4.6	40

16	New uses for old copper-binding drugs: converting the pro-angiogenic copper to a specific cancer cell death inducer. *Expert Opinion on Therapeutic Targets*, **2008**, 12, 739-48	6.4	49
15	Pristimerin induces apoptosis by targeting the proteasome in prostate cancer cells. *Journal of Cellular Biochemistry*, **2008**, 103, 234-44	4.7	77
14	Relationship between the methylation status of dietary flavonoids and their growth-inhibitory and apoptosis-inducing activities in human cancer cells. *Journal of Cellular Biochemistry*, **2008**, 105, 514-23	4.7	55
13	Calpain-mediated androgen receptor breakdown in apoptotic prostate cancer cells. *Journal of Cellular Physiology*, **2008**, 217, 569-76	7	35
12	Methylation suppresses the proteasome-inhibitory function of green tea polyphenols. *Journal of Cellular Physiology*, **2007**, 213, 252-60	7	60
11	Lessons learned from Art Pardee in cell cycle, science, and life. *Journal of Cellular Physiology*, **2006**, 209, 663-9	7	
10	The proteasome as a potential target for novel anticancer drugs and chemosensitizers. *Drug Resistance Updates*, **2006**, 9, 263-73	23.2	119
9	Structure-activity study of epi-gallocatechin gallate (EGCG) analogs as proteasome inhibitors. *Bioorganic and Medicinal Chemistry*, **2005**, 13, 2177-85	3.4	46
8	Direct inhibition of interleukin-2 receptor alpha-mediated signaling pathway induces G1 arrest and apoptosis in human head-and-neck cancer cells. *Journal of Cellular Biochemistry*, **2005**, 95, 379-90	4.7	5
7	Evaluation of proteasome-inhibitory and apoptosis-inducing potencies of novel (-)-EGCG analogs and their prodrugs. *International Journal of Molecular Medicine*, **2005**, 15, 735-42	4.4	36
6	Novel N-thiolated beta-lactam antibiotics selectively induce apoptosis in human tumor and transformed, but not normal or nontransformed, cells. *Biochemical Pharmacology*, **2004**, 67, 365-74	6	60
5	Organic copper complexes as a new class of proteasome inhibitors and apoptosis inducers in human cancer cells. *Biochemical Pharmacology*, **2004**, 67, 1139-51	6	231
4	Docking studies and model development of tea polyphenol proteasome inhibitors: applications to rational drug design. *Proteins: Structure, Function and Bioinformatics*, **2004**, 54, 58-70	4.2	91
3	Direct inhibition of the ubiquitin-proteasome pathway by ester bond-containing green tea polyphenols is associated with increased expression of sterol regulatory element-binding protein 2 and LDL receptor. *Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids*, **2004**, 1682, 1-10	5	59
2	G(1) phase-dependent expression of bcl-2 mRNA and protein correlates with chemoresistance of human cancer cells. *Molecular Pharmacology*, **2000**, 58, 1001-10	4.3	43
1	Putative roles of retinoblastoma protein in apoptosis. *Apoptosis: an International Journal on Programmed Cell Death*, **1997**, 2, 5-18	5.4	15